Cardiology · Transcatheter Aortic Valve ReplacementTrial Updatecompetitivemid-term

SELECT TAVR Trial to Compare Myval and Evolut Valves in Borderline Annuli Patients

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 6:02:55 AM

Assessment confidence: 72% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The SELECT TAVR trial's outcomes could significantly impact the competitive landscape for transcatheter heart valves, particularly between Myval and Evolut. If Myval demonstrates non-inferiority or superiority, it may shift clinical practices and market share in TAVI procedures, especially for patients with complex anatomical profiles. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 5 ranked evidence items (3 high-relevance).

Strategic Assessment

Success in the SELECT TAVR trial may lead to increased adoption of Myval valves, impacting market share and clinical practices in TAVI procedures. The strongest clinical anchor is Selection of Transcatheter Heart vaLve With Intermediate Sizing in Patients With Severe Aortic Stenosis Treated With Transcatheter Aortic Valve Replacement (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In cardiology, 3 regulatory and 2 competitive items passed relevance filtering for Myval.

Competitive Pressure

The most relevant competitive pressure comes from AstraZeneca's Wainua fails primary endpoint in ATTR-CM Phase III trial (Humanexa Signals) — sub-indication match (cardiology); sponsor/company relevance (astrazeneca). Secondary pressure from SINGLE-AF Trial Evaluates DOACs in Intermediate Stroke Risk Atrial Fibrillation Patients.

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). The trial results may influence future regulatory considerations and approvals for Myval, particularly regarding its expanded sizing options and safety profiles.

Key Risks

Elevated medium regulatory exposure for Myval could delay market entry or constrain labeling if agency review intensifies.
Competitive risk from Humanexa Signals (AstraZeneca's Wainua fails primary endpoint in ATTR-CM Phase III trial) could weigh on Myval through competitive crowding and share erosion if follow-through weakens.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Myval through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

A successful trial for Myval could lead to increased adoption and market share, directly affecting revenue streams for both Myval and Evolut in the TAVI market.
Cardiology · ATTR-CM · Trial Update · This failure may impact AstraZeneca and Ionis' competitive positioning in the ATTR-CM market, potentially opening opportunities for competitors.
Upside for Myval may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Success in the SELECT TAVR trial may lead to increased adoption of Myval valves, impacting market share and clinical practices in TAVI procedures.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for safety and hemodynamic performance metrics at 30 days and longer-term follow-up outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Condition-Specific Meeting Reports and Other Information Related to Patients' Experience
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Borderline products: how to tell if your product is a medicine
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Selection of Transcatheter Heart vaLve With Intermediate Sizing in Patients With Severe Aortic Stenosis Treated With Transcatheter Aortic Valve Replacement
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Trial of Treatments for COVID-19 in Hospitalized Adults
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

AstraZeneca's Wainua fails primary endpoint in ATTR-CM Phase III trial
Humanexa Signalshigh relevance
Sub-indication match (cardiology); Sponsor/company relevance (AstraZeneca)
SINGLE-AF Trial Evaluates DOACs in Intermediate Stroke Risk Atrial Fibrillation Patients
Humanexa Signalshigh relevance
Sub-indication match (cardiology)
Biogen's Felzartamab Study Targets Isolated Microvascular Inflammation in Kidney Transplant Patients
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Myval
Evolut

Commercial impact

high

A successful trial for Myval could lead to increased adoption and market share, directly affecting revenue streams for both Myval and Evolut in the TAVI market.

Regulatory impact

medium

The trial results may influence future regulatory considerations and approvals for Myval, particularly regarding its expanded sizing options and safety profiles.

What to watch

Monitor trial results for safety and hemodynamic performance metrics at 30 days and longer-term follow-up outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.